Background: Decidual Natural Killer (dNK) cells are expressed slightly in the maternal fetal interface and serve the trophoblast to invaded decidual tissue in normal pregnancy. In preeclampsia, Decidual Natural Killer (dNK) expression increases as a result of maternal immune maladaptation, causing the decreased of VEGF expression. Recombinant VEGF-121 therapy is thought to decrease the expression of dNK cells. This study aims to determine the effect of recombinant VEGF-121 on dNK cell expression in preeclampsia mice model. Methods: Experimental. The sample size was 30 pregnant mice divided into 3 groups: 10 normal pregnant mice (N), 10 preeclampsia pregnant mice models, (PE) and 10 preeclampsia mice model with recombinant VEGF-121 therapy (VEGF). Preeclampsia mice model was made with injection of an intra venous 10 ng anti-Qa-2 which would eliminate the expression of Qa-2 (homologous HLA-G in humans) from day 1 to 4th of pregnancy. Recombinant VEGF-121 therapy is administered on the 12th to 15th day of pregnant mice with an intravenaous injection of 125 mg / kgBW / day. On day 16, all samples were examined of dNK/ CD56 by using Immunohistochemical methods. Data were analyzed by using Kruskal Wallis and Mann Whitney test. Result: Mean of dNK/ CD56 cell in N group =1.20±0.62; PE group =2.32±1.33 with p value =0.01. Mean of dNK/ CD56 cells in VEGF group =2,25±0,94, with p value =0.02. Conclusions: Recombinant VEGF-121 therapy had an effect on decreasing dNK/ CD56 cells in preeclampsia mice model.
